Numerous media have already reported about the development and work of Orphanbiotec. It is particularly pleasing that our work and concept is cited in the 2011 Swiss Foundation report as an innovative best-practice example of a start-up in the field of philanthropy. We operate an innovative network, promoted by our patient engagement program, with the vision to motivate patients affected by rare disease and encourage them to break out of their isolation and be actively involved. We received the 2011 Social Entrepreneurship Award from SEF which confirms our position and vision. Our goal is to reflect, on social entrepreneurship, the need for alternative business models in the pharmaceutical sector. Read more about this need. www.wirtschaftsmagazin.ch
The innovative hybrid business model of Orphanbiotec consists of a Foundation, which finances the first steps in research and development (pre-clinical development) and a sustainable partnership with pharmaceutical partners (a Company has been established to be our first partner). This partner further finances the cost of drug development to bring the orphan drug to market. In return for the Foundation’s initial commitment the partner pays an agreed annual social benefit back to the Foundation for the patent life of the orphan drug. Thus allowing the Foundation to kick-off additional partnering projects.
